[ET Net News Agency, 25 October 2021] UBS initiates coverage of Alphamab (09966) with a
target price of HK$29.6 and a "buy" rating.
The research house said it expects Alphamab's risk-adjusted peak sales to reach RMB7.5bn
and thinks its lower-than-peer risk-adjusted 1.8x market cap/peak year revenue (P/PS) does
not fully price in its asset value and strong in-house R&D capability. (RC)